Open access
Open access
Powered by Google Translator Translator

Covid-19

Cohort study: Risk factors for long covid in previously hospitalized children.

3 Aug, 2021 | 09:06h | UTC

Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study – European Respiratory Review

Commentaries:

Study investigates long-term sequelae of COVID-19 in hospitalized children – News Medical

 

Commentary on Twitter

 


A blood marker predicts who gets ‘breakthrough’ COVID (neutralizing antibodies).

3 Aug, 2021 | 09:01h | UTC

A blood marker predicts who gets ‘breakthrough’ COVID – Nature

Related:

A correlate of protection for SARS-CoV-2 vaccines is urgently needed – “Recent studies suggest that neutralizing antibodies could serve as a correlate of protection for vaccines against SARS-CoV-2 in humans”.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

Covid-19 breakthrough infections in vaccinated health care workers.

 


Postacute Sequelae of COVID-19 Pneumonia: 6-month Chest CT Follow-up.

3 Aug, 2021 | 09:02h | UTC

Postacute Sequelae of COVID-19 Pneumonia: 6-month Chest CT Follow-up – Radiology

 


Covid: Pulse oxygen monitors work less well on darker skin, experts say.

3 Aug, 2021 | 09:00h | UTC

Covid: Pulse oxygen monitors work less well on darker skin, experts say – BBC

Related:

FDA issues alert on ‘limitations’ of pulse oximeters, without explicit mention of racial bias

“Racial Bias in Pulse Oximetry Measurement”. In two large cohorts, Black patients had nearly three times the frequency of occult hypoxemia that was not detected by pulse oximetry as White patients

 


WHO special envoys: To beat Covid, there’s a simple lesson – no one’s safe until everyone’s safe.

3 Aug, 2021 | 08:58h | UTC

To beat Covid, there’s a simple lesson – no one’s safe until everyone’s safe – The Guardian

 

Commentary on Twitter

 


Opinion | Should pregnant women have a COVID vaccine? The evidence says it’s safe and effective.

2 Aug, 2021 | 00:28h | UTC

Should pregnant women have a COVID vaccine? The evidence says it’s safe and effective – The Conversation

 


The study behind new CDC’s mask guidance found vaccinated people can spread delta variant.

2 Aug, 2021 | 00:33h | UTC

CDC Report: Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021 – Centers for Disease Control and Prevention

Commentaries:

The Study Behind CDC’s Mask Guidance Found Vaccinated People Can Spread Delta Variant – NPR

What Delta has changed in the Covid pandemic — and what it hasn’t – STAT

 

Commentary on Twitter (thread – click for more)

 


Guideline: Clinical management of adult patients with COVID-19 Outside Intensive Care Units.

2 Aug, 2021 | 00:26h | UTC

Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) – Infectious Diseases and Therapy

 


How the coronavirus infects cells — and why Delta is so dangerous.

2 Aug, 2021 | 00:22h | UTC

How the coronavirus infects cells — and why Delta is so dangerous – Nature

 


ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

2 Aug, 2021 | 00:31h | UTC

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM)

Additional reading:

Practice Advisory: COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care

COVID-19 Vaccines and Pregnancy: Conversation Guide for Clinicians

Commentaries:

Obstetrician groups recommend COVID vaccine during pregnancy – Associated Press

Statements By Obstetrics Societies Strongly Advise Covid-19 Vaccinations For Pregnant Women – Forbes

 

Commentary on Twitter

 


Post-viral effects of COVID-19 in the olfactory system and their implications.

2 Aug, 2021 | 00:24h | UTC

Post-viral effects of COVID-19 in the olfactory system and their implications – The Lancet Neurology

Related:

Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis.

Eight out of ten people hospitalized with COVID-19 develop neurological problems – the most common self-reported symptoms included headache (37%) and anosmia or ageusia (26%).

Loss of smell in mild Covid-19 cases occurs 86% of the time, study says

Management of anosmia and loss of smell in the era of Covid-19

 


What every intensivist should know about Tocilizumab.

2 Aug, 2021 | 00:25h | UTC

What every intensivist should know about Tocilizumab – Critical Care

Related:

Tocilizumab in COVID-19 therapy: who benefits, and how?

A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19.

M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less.

M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

 


COVID boosters for wealthy nations spark outrage.

2 Aug, 2021 | 00:21h | UTC

COVID boosters for wealthy nations spark outrage – Nature

Related: MSF: No COVID-19 booster shots anywhere before healthcare workers and vulnerable people everywhere have access – Médecins Sans Frontières/Doctors Without Borders

 


Scientists Grapple with Question of COVID-19 Vaccine Booster, as Some Countries Push Ahead.

2 Aug, 2021 | 00:19h | UTC

Scientists Grapple With Question of COVID-19 Vaccine Booster, as Some Countries Push Ahead – Health Policy Watch

 


Viewpoint: The road to addressing Long Covid.

30 Jul, 2021 | 12:09h | UTC

The road to addressing Long Covid – Science (a few articles per month are free)

Related: Review: Long covid—mechanisms, risk factors, and management.

 

Commentary on Twitter

 


NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

30 Jul, 2021 | 12:14h | UTC

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis – National Institute for Health and Care Excellence

News release: NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination – National Institute for Health and Care Excellence

Related: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 


Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

30 Jul, 2021 | 12:12h | UTC

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know – Blood

Related: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 


Study: Patients who have recovered from COVID-19 may have persistent cognitive symptoms.

30 Jul, 2021 | 12:03h | UTC

Cognitive deficits in people who have recovered from COVID-19 – EClinicalMedicine

 

Commentary on Twitter (thread – click for more)

 


Risk of acute myocardial infarction and ischemic stroke following COVID-19 in Sweden – “the true risk is increased by between three and eight times for acute myocardial infarction and by between three and seven times for ischaemic stroke following COVID-19.”

30 Jul, 2021 | 12:06h | UTC

Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study – The Lancet

Invited commentary: What is the association of COVID-19 with heart attacks and strokes? – The Lancet

 

Commentary on Twitter

 


Self-reported memory problems 8 months after COVID-19 infection.

30 Jul, 2021 | 12:02h | UTC

Self-reported Memory Problems 8 Months After COVID-19 Infection – JAMA Network Open

Commentary: Post-acute Sequelae of SARS-CoV-2 Infection and Subjective Memory Problems – JAMA Network Open

 

Commentary on Twitter (thread – click for more)

 


Israel to offer 3rd COVID booster shot to older citizens.

30 Jul, 2021 | 11:57h | UTC

Israel to offer 3rd COVID booster shot to older citizens – Associated Press

 


Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

29 Jul, 2021 | 11:38h | UTC

Ivermectin for preventing and treating COVID‐19 – Cochrane Library

Summary: Ivermectin for preventing and treating COVID-19 – Cochrane Library

Commentary: Ivermectin treatment in humans for COVID-19 – Liverpool School of Tropical Medicine

Related:

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 


Updated WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply.

29 Jul, 2021 | 11:34h | UTC

WHO SAGE Roadmap For Prioritizing Uses Of COVID-19 Vaccines In The Context Of Limited Supply – World Health Organization

 


PRINCIPLE RCT: Doxycycline does not improve outcomes in outpatients with suspected COVID-19 at high risk for adverse outcomes.

29 Jul, 2021 | 11:36h | UTC

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet Respiratory Medicine

Commentary: PRINCIPLE: a community-based COVID-19 platform trial – The Lancet Respiratory Medicine

 

Commentary on Twitter

 


Covid-19 breakthrough infections in vaccinated health care workers.

29 Jul, 2021 | 11:30h | UTC

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers – New England Journal of Medicine

 

Commentary on Twitter (thread – click for more)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.